Literature DB >> 7449119

Homogeneous substrate-labeled fluorescent immunoassay for theophylline in serum.

T M Li, J L Benovic, R T Buckler, J F Burd.   

Abstract

A substrate-labeled fluorescent immunoassay for theophylline in serum is described. 8-(3-Aminopropyl)-theophylline is covalently attached to a fluorogenic enzyme substrate, 7-beta-galactosylcoumarin-3-carboxylic acid. Hydrolysis of this theophylline-labeled substrate by beta-galactosidase yields a fluorescent product. When antibody to theophylline interacts with this substrate, the resulting complex is inactive as an enzyme substrate. For measuring theophylline, competitive protein-binding reactions are set up, with the theophylline in the sample competing with the substrate for the antibody-binding sites. The substrate not bound to antibody is hydrolyzed by beta-galactosidase, producing fluorescence that is proportional to the theophylline concentration. Results for theophylline determined by this method in clinical samples of serum correlated well (r > 0.96) with results obtained by gas-chromatographic or enzyme immunoassay procedures. The within-run CV for three control samples ranged from 1.1 to 2.8%, the between-run CB from 2.3 to 4.5%.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7449119

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Homogeneous immunoassays.

Authors:  R C Boguslaski; T M Li
Journal:  Appl Biochem Biotechnol       Date:  1982-09       Impact factor: 2.926

2.  Transdermal delivery of theophylline to premature infants using a hydrogel disc system.

Authors:  R G Cartwright; P H Cartlidge; N Rutter; C D Melia; S S Davis
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 3.  Drug interferences with plasma assays in therapeutic drug monitoring.

Authors:  S Yosselson-Superstine
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

4.  Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma.

Authors:  S G Hibberd; C Alveyn; E J Coombes; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

5.  A double-blind comparative trial between two sustained-release theophylline preparations with individual doses in asthmatic in-patients.

Authors:  Y G Van der Meer; A C Van Alphen; R Van Altena; A C Van Loenen
Journal:  Pharm Weekbl Sci       Date:  1982-12-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.